Stephen Montaquila
Optometrist · Warwick, RINPI 1326003674
Payments from drug & device makers
Across 1,817 payments — averaging $1070.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$986K
- Johnson & Johnson Vision Care, Inc.$486K
- Oyster Point Pharma, Inc.$152K
- AbbVie$87K
- Bausch Health US, LLC$81K
- Sight Sciences, Inc.$69K
- plus $84K from 13 others
Across 6 payments — averaging $10,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$34K
- Coopervision Inc.$28K
What the payments were for
- Consulting fees$27,66154%
- Speaking & faculty fees$10,27520%
- Travel & lodging$6,10712%
- Food & beverage$7,03714%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1,423 | $985,979 |
| Johnson & Johnson Vision Care, Inc. | 110 | $485,612 |
| Oyster Point Pharma, Inc. | 35 | $152,446 |
| AbbVie(2 entities) | 45 | $86,911 |
| Bausch Health US, LLC | 4 | $81,420 |
| Sight Sciences, Inc. | 15 | $68,526 |
| Bausch & Lomb Americas Inc. | 50 | $53,110 |
| Glaukos Corporation | 11 | $21,964 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $5,875 |
| Alcon | 23 | $1,307 |
| Sun Pharmaceutical Industries Inc. | 33 | $607 |
| Tarsus Pharmaceuticals, Inc. | 11 | $276 |
| Dompe US, Inc. | 9 | $246 |
| Coopervision Inc. | 10 | $243 |
| Novartis | 7 | $130 |
| Kala Pharmaceuticals, Inc. | 3 | $54 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Thea Pharma Inc. | 2 | $36 |
| Aerie Pharmaceuticals, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RADIUS$21,964
- INFUSE$12,371
- BIOTRUE$2,263
- ULTRA$2,263
- BIOTRUE ONE DAY$2,263
- TEARCARE SYSTEM$2,200
- ULTRA MULTIFOCAL TORIC$2,000
- TearCare$106
- VYZULTA$101
How this compares
$1,944,811 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $35,174 |
| LumiganBimatoprost | 23 | $10,243 |
| Bromfenac Sodium | 14 | $1,592 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 19 | $1,480 |
| Fluorometholone | 11 | $1,227 |
| Latanoprost | 69 | $1,144 |
| Timolol Maleate | 44 | $781 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $765 |
| Doxycycline Monohydrate | 13 | $348 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $254 |
| Brimonidine Tartrate | 12 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $86,911 | $45,41749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 optometrist providers in Rhode Island.
Other optometrist in Warwick
- Maria SampalisWarwick$135K
- Matthew DoyleWarwick$9K
- Georgia PatsiopoulosWarwick$9K
- Alyssa CampagnoneWarwick$5K
- Earle ScharffWarwick$4K
- Lam DaoWarwick$3K
- Kristin BrennanWarwick$3K
- Michele PalazzoloWarwick$2K
- Iris MillerWarwick$2K
- Tiffany GrahamWarwick$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.